Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Than Half Of Trials Conducted In South Korea Led By Pfizer

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The number of clinical trials Pfizer Korea conducted in South Korea last year rose sharply to 93 cases from 75 cases in 2007, a result of Pfizer's move to conduct more of its clinical trials in South Korea

You may also be interested in...



Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 1 of 2)

Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company has several business segments including clinical trials, and contract manufacturing and sales, and operates in Japan, the United States, South Korea, Taiwan, Singapore, and China. CMIC's CRO business accounted for 58 percent of its sales. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News Japan bureauto give his perspectives on clinical trials in Japan and other Asian countries under the influence of the International Conference on Harmonization.

Japan's First CRO CMIC On How ICH Affects Clinical Trials in Japan: An Interview with PharmAsia News (Part 1 of 2)

Established in 1992 as the first contract clinical trial research organization in Japan, CMIC is now one of the largest Japanese CROs and currently employs more than 2,500 employees. The company has several business segments including clinical trials, and contract manufacturing and sales, and operates in Japan, the United States, South Korea, Taiwan, Singapore, and China. CMIC's CRO business accounted for 58 percent of its sales. CMIC Corporate Officer Asia Development Moriaki Akasaki sat down with PharmAsia News Japan bureauto give his perspectives on clinical trials in Japan and other Asian countries under the influence of the International Conference on Harmonization.

Japan's First CRO On How ICH Affects Clinical Trials in Japan: An Interview With CMIC Exec Moriaki Akasaki

CMIC was established in 1992 and now is Japan's largest contract research organization, with more than 2,500 employees.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel